Another trial of treating recurrent HCC patients with percutaneous radiofrequency ablation showed that post-recurrence survival of patients who relapsed and were treated within the same tumor lesion was higher than those with generated distant recurrence or those with BCLB C recurrence (averages: 39 months vs. 27 months vs. 7 months, respectively) [62], suggesting the substaintial role of TME in HCC. The gene discussed is BCL2L10; the disease is hepatocellular carcinoma.